Patents Assigned to Ligand Pharmaceuticals Incorporated
  • Patent number: 12208071
    Abstract: Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: January 28, 2025
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Lin Zhi, Ian Henderson, Joseph Kaloko, Martin Osterhout
  • Patent number: 11773110
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: October 3, 2023
    Assignee: LIGAND PHARMACEUTICALS INCORPORATED
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Patent number: 11358931
    Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: June 14, 2022
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 11278559
    Abstract: Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: March 22, 2022
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 11186593
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: November 30, 2021
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Patent number: 10874638
    Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: December 29, 2020
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 10730831
    Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: August 4, 2020
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 10604533
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 31, 2020
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Patent number: 10441567
    Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions. Specifically, a composition that includes an effective amount of a selective estrogen receptor modulator (SERM) and an effective amount of a 5a-reductase inhibitor, or a pharmaceutically acceptable salt, ester or prodrug of the foregoing is provided. Also provided are methods for the treatment of aging related conditions and diseases.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: October 15, 2019
    Assignee: LIGAND PHARMACEUTICALS INCORPORATED
    Inventor: Lin Zhi
  • Patent number: 10420748
    Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 24, 2019
    Assignee: LIGAND PHARMACEUTICALS INCORPORATED
    Inventors: Keith B. Marschke, Lin Zhi
  • Patent number: 10106500
    Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 23, 2018
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 10030034
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: July 24, 2018
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Patent number: 10000522
    Abstract: Some embodiments of the present invention include nucleoside 5?-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 19, 2018
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 9962370
    Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 8, 2018
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Keith B. Marschke, Lin Zhi
  • Patent number: 9675583
    Abstract: Provided herein are compounds, such as compounds, of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: June 13, 2017
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 9676809
    Abstract: Some embodiments of the present invention include nucleoside 5?-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: June 13, 2017
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 9492430
    Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: November 15, 2016
    Assignee: Ligand Pharmaceuticals, Incorporated
    Inventors: Lin Zhi, Keith Marschke, Virginia H. Grant, Steven L. Roach, Yixing Shen, Jason C. Pickens, Bijan Pedram, C. Arjan van Oeveren, Lino J. Valdez, Andrew R. Hudson
  • Patent number: 9359285
    Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: June 7, 2016
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Lin Zhi, Robert I. Higuchi, Cornelis Arjan Van Oeveren, Thomas Lot Stevens Lau
  • Patent number: 9266874
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 23, 2016
    Assignee: LIGAND PHARMACEUTICALS INCORPORATED
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Patent number: 9139520
    Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: September 22, 2015
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi